Corvus Pharmaceuticals, Inc.

CRVS

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001626971

SEC filings (opens in a new tab)

No open-market purchases or sales by Corvus Pharmaceuticals, Inc. insiders were filed in the last 90 days; 173 institutions reported holding it in 13F filings for Q2 2026, worth $1.06B in total; no superinvestor holds it.

Q1 2022 vs. Q4 2021

How the institutions holding Corvus Pharmaceuticals, Inc. changed between Q4 2021 and Q1 2022.

All holders in Q1 2022 All holders in Q4 2021

13F holders of CRVS: Q4 2021 compared with Q1 2022
Measure	Q4 2021	Q1 2022	Change
Holders	62	57	−5
Shares	27.7M	27.4M	−274.7K (−1.0%)
Value	$66.7M	$44.9M	−$21.8M (−32.6%)

New holders (7)

Institutions that held Corvus Pharmaceuticals, Inc. at the end of Q1 2022 but not at the end of Q4 2021.

Institutions new to CRVS in Q1 2022
Institution	Shares	Value	% of portfolio
Jackson Square Capital, LLC	63,773	$105.0K	0.03%
ExodusPoint Capital Management, LP	25,563	$42.0K	0.00%
Simplex Trading, LLC	20,074	$32.0K	0.00%
Susquehanna Fundamental Investments, LLC	13,790	$23.0K	0.00%
Virtu Financial LLC	14,269	$23.0K	0.00%
US Bancorp	5,153	$8.00K	0.00%
Meeder Asset Management Inc	977	$2.00K	0.00%

Sold out (12)

Institutions that held Corvus Pharmaceuticals, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.

Institutions that sold out of CRVS in Q1 2022
Institution	Shares, Q4 2021	Value, Q4 2021
Anson Funds Management LP	528,358	$1.27M
VR Adviser, LLC	250,000	$603.0K
Jump Financial, LLC	55,500	$134.0K
Caxton Associates LP	43,325	$104.0K
Dynamic Technology Lab Private Ltd	20,168	$49.0K
Squarepoint Ops LLC	13,118	$32.0K
Charles Schwab Investment Management Inc	11,217	$28.0K
Engineers Gate Manager LP	11,814	$28.0K
The PNC Financial Services Group, Inc.	3,000	$7.00K
Masso Torrence Wealth Management Inc.	2,731	$7.00K
Total Clarity Wealth Management, Inc.	500	$1.00K
Amplius Wealth Advisors, LLC	586	$1.00K